Article Sidebar

Submitted
July 24, 2024
Accepted
August 29, 2025
Published
August 31, 2025
Download
PDF
Statistic
Read Counter : 283 Download : 221

Downloads

Download data is not yet available.

Main Article Content

Abstract

Pendahuluan: Pengertian dari gagal jantung adalah sebuah sindroma klinis dimana jantung mengalami kegagalan dalam menjalankan tugasnya baik. Fungsi dari Beta- blocker adalah menghambat adrenoreseptor beta di jantung, pembuluh darah perifer, bronkus, pankreas, dan hati. Artikel ini menjelaskan mengenai kegunaan Beta- blocker pada pasien gagal jantung dengan fraksi ejeksi yang menurun beserta pengaruhnya terhadap komorbid kardiovaskular dan non kardiovaskular.
Pembahasan: Beta-blocker merupakan terapi yang direkomendasikan diberikan pada pasien heart failure dengan ejection fraction yang menurun. Obat golongan beta-blocker membantu mencegah gejala heart failure, meningkatkan remodeling ventrikel kiri, menurunkan resiko rawat inap dan kematian dini. Beta-blocker tidak digunakan pada gangguan nafas fase akut karena dapat memperburuk gagal jantung, bradikardia atau blok jantung dan hipotensi. Pemberian beta-blocker juga direkomendasikan pada pasien aritmia karena berperan dalam kontrol laju ventrikel serta memperlihatkan mortalitas yang lebih rendah dan prognosis yang lebih baik pada pasien atrial fibrilasi yang mendapatkan terapi beta-blocker.
Kesimpulan: Beta-blocker direkomendasikan sebagai terapi pada pasien gagal jantung dengan fraksi ejeksi menurun. Tetapi, perlu diperhatikan adanya komorbid kardiovaskular maupun non-kardiovaskular yang dapat mempengaruhi pemberian terapi beta-blockers. Pemberian terapi beta-blocker diharapkan dapat mengurangi mortalitas atau morbiditas pada pasien gagal jantung dengan fraksi ejeksi yang berkurang (HFrEF).

Keywords

HFrEF komorbid beta blocker

Article Details

License
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Purwowiyoto, S. L., Dwi Delima, F. S., Batuul, M., & Saputra, A. (2025). Penggunaan Β-Blockers Pada Pasien Gagal Jantung Fraksi Ejeksi Menurun . Sanus Medical Journal, 7(1), 1–20. https://doi.org/10.22236/sanus.v7i1.15792
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Laksono S. Seri Kardiologi Praktis Gagal Jantung: Bintang Pustaka. Bintang Pustaka Madani; 2021.
  2. Rampengan SH. Peran Terkini Beta Bloker pada Pengobatan Kardiovaskular. Universitas Indonesia Publishing; 2014.
  3. Sari OM, Cahaya N, Susilo YH. Studi Penggunaan Obat Golongan Beta-Blocker Pada Pasien Rawat Inap Rumah Sakit Ansari Saleh Banjarmasin. Jurnal Farmasi Udayana 2020;9:123.
  4. https://doi.org/10.24843/JFU.2020.v09.i02.p07
  5. Stolfo D, Uijl A, Benson L, Schrage B, Fudim M, Asselbergs FW, et al. Association between beta‐blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score‐matched analysis from the Swedish Heart Failure Registry. Eur J Heart Fail 2020;22:103-12.
  6. https://doi.org/10.1002/ejhf.1615
  7. Laksono S, Pratama AP, Halomoan R, Andra CA. A Short Review of New Drugs for Heart Failure: Omecamtiv Mecarbil and Vericiguat. Journal of Drug Delivery and Therapeutics 2022;12:206-9. https://doi.org/10.22270/jddt.v12i2-S.5432.
  8. https://doi.org/10.22270/jddt.v12i2-S.5432
  9. Liver EA for TS of the. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406-60.
  10. https://doi.org/10.1016/j.jhep.2018.03.024
  11. Dhillon J. Tantangan Diagnostik dan Penanganan PPOK yang Tumpang Tindih dengan Gagal Jantung. Cermin Dunia Kedokteran 2016;43:713-6.
  12. Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. European Respiratory Journal 2016;48:880-8.
  13. https://doi.org/10.1183/13993003.01847-2015
  14. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. Heart Fail Rev 2018;23:303-23.
  15. https://doi.org/10.1007/s10741-018-9685-0
  16. Bell DSH, Goncalves E. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications. Diabetes Obes Metab 2019;21:1277-90.
  17. https://doi.org/10.1111/dom.13652
  18. Laksono S, Nurapipah P, Nurusshofa Z, Rininta R. Role of Primary Care in Management of Heart Failure Preserved Ejection Fraction (HFpEF): A Literature Review. Journal of Drug Delivery and Therapeutics 2022;12:221-4. https://doi.org/10.22270/jddt.v12i3-S.5508.
  19. https://doi.org/10.22270/jddt.v12i3-S.5508
  20. Indonesia PDSK. Panduan Praktik Klinis dan Clinical Pathway Penyakit Jantung dan Pembuluh Darah (Edisi Pertama). Jakarta: PERKI 2016:38-42.
  21. Cadrin-Tourigny J, Shohoudi A, Roy D, Talajic M, Tadros R, Mondésert B, et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy. JACC Heart Fail 2017;5:99-106.
  22. https://doi.org/10.1016/j.jchf.2016.10.015
  23. Masarone D, Martucci ML, Errigo V, Pacileo G. The use of β-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 2021;8:101.
  24. https://doi.org/10.3390/jcdd8090101
  25. Manolis A, Doumas M, Ferri C, Mancia G. Erectile dysfunction and adherence to antihypertensive therapy: focus on β-blockers. Eur J Intern Med 2020;81:1-6.
  26. https://doi.org/10.1016/j.ejim.2020.07.009
  27. Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. Bmj 2016;353.
  28. https://doi.org/10.1136/bmj.i1855
  29. Málek F. Reaching betablockers target dose in elderly patients with chronic heart failure. Cor Vasa 2014;56:e37-41.
  30. https://doi.org/10.1016/j.crvasa.2014.01.001
  31. Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: a literature review. Indian Heart J 2017;69:545-50.
  32. https://doi.org/10.1016/j.ihj.2017.07.004
  33. Tagami T, Yambe Y, Tanaka T, Tanaka T, Ogo A, Yoshizumi H, et al. Short-term effects of β-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves' disease. Internal Medicine 2012;51:2285-90.
  34. https://doi.org/10.2169/internalmedicine.51.7302
  35. Khan R, Sikanderkhel S, Gui J, Adeniyi A-R, O'Dell K, Erickson M, et al. Thyroid and cardiovascular disease: a focused review on the impact of hyperthyroidism in heart failure. Cardiol Res 2020;11:68.
  36. https://doi.org/10.14740/cr1034
  37. Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations. JHEP Reports 2020;2:100063.
  38. https://doi.org/10.1016/j.jhepr.2019.12.001
  39. Wu VC, Chen S, Ting P, Chang C, Wu M, Lin M, et al. Selection of β‐Blocker in Patients With Cirrhosis and Acute Myocardial Infarction: A 13‐Year Nationwide Population‐Based Study in Asia. J Am Heart Assoc 2018;7:e008982.
  40. https://doi.org/10.1161/JAHA.118.008982